Table 2 Malignant networks also are partly activated by oxaliplatin treatment, indicating an inherent competition between efficacy and toxicity which can be characterized based on high throughput analysis
From: Network insights on oxaliplatin anti-cancer mechanisms
Overview of some signaling changes upon oxaliplatin treatment | |||
|---|---|---|---|
Signaling network | Molecules in dataset | # Up regulated | # Down regulated |
Ovarian Cancer | 64 | 34 | 30 |
Glioma Signaling | 50 | 26 | 24 |
Prostate Cancer | 53 | 31 | 22 |
Non-Small Cell Lung Cancer | 39 | 25 | 14 |
Colorectal Cancer Metastasis | 116 | 59 | 57 |
Basal Cell Carcinoma | 25 | 13 | 12 |
Melanoma | 25 | 14 | 11 |
Small Cell Lung Cancer | 47 | 28 | 19 |
VEGF | 49 | 25 | 24 |
Renal Cell Carcinoma | 45 | 30 | 15 |
Sonic Hedgehog | 15 | 7 | 8 |
Pancreatic Adenocarcinoma | 65 | 37 | 28 |